Risk of Posterior Capsular Rupture during Phacoemulsification in Patients with the History of Anti-VEGF Intravitreal Injections: Results from the Pan-American Collaborative Retina Study (PACORES) Group.

Autor: Velez-Montoya R; Retina Department, Asociación para Evitar le Ceguera en México IAP, México City 04030, Mexico., Sanchez-Santos I; Retina Department, Asociación para Evitar le Ceguera en México IAP, México City 04030, Mexico., Galvan-Chavez M; Retina Department, Asociación para Evitar le Ceguera en México IAP, México City 04030, Mexico., Wu L; Asociados de Macula, Vitreo y Retina de Costa Rica, San Jose City 10102, Costa Rica., Arevalo JF; Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA., Berrocal MH; Department of Ophthalmology, University of Puerto Rico, San Juan, PR 00907, USA., Alezzandrini AA; Ophthalmology Department, University of Buenos Aires, School of Medicine, Buenos Aires C1121, Argentina., Figueroa MS; Retina and Vitreous Department, Hospital Universitario Ramón y Cajal, Madrid 28034, Spain., Gallego-Pinazo R; Ophthalmology Department, Hospital Universitario y Politécnico La Fe, Valencia 46026, Spain., Dolz-Marco R; Ophthalmology Department, Hospital Universitario y Politécnico La Fe, Valencia 46026, Spain., Martinez-Rubio C; Ophthalmology Department, Hospital Universitario y Politécnico La Fe, Valencia 46026, Spain., Gonzalez-Salinas R; Anterior Segment Department, Asociación para Evitar le Ceguera en México IAP, DF 04030, México City, Mexico.
Jazyk: angličtina
Zdroj: Journal of ophthalmology [J Ophthalmol] 2021 Oct 11; Vol. 2021, pp. 5591865. Date of Electronic Publication: 2021 Oct 11 (Print Publication: 2021).
DOI: 10.1155/2021/5591865
Abstrakt: Purpose: To assess the risk for capsular rupture during routine phacoemulsification in patients with a history of anti-VEGF injections and other possible risk modifiers such as treatment patterns, type of anti-VEGF agent, and experience of the surgeon, among others.
Methods: This study reviewed the medical records of 11,129 patients from 7 different hospitals in 5 countries. The study included 939 patients that underwent routine phacoemulsification and had a history of anti-VEGF therapy. We excluded patients with known risk factors for capsular rupture, as well as patients with a history of other retinal procedures. The study extracted data regarding general demographics, the number of previous injections, type of anti-VEGF agent, details of cataract surgery, and anti-VEGF treatment patterns.
Results: Overall prevalence of posterior capsular rupture: 7.45% (95% CI: 5.9-9.32%). The mean number of injections per patient was 3.37 ± 2.8. More than 50% of the patients received their last anti-VEGF injection within three months before cataract surgery. The complication rate during intravitreal injections was 1.07%. In the univariate analysis, the experience of the cataract surgeon (inexperience surgeons; OR: 2.93) and the history of prior anti-VEGF therapy (OR: 1.77) were significant risk indicators for PCR ( p < 0.05). However, after controlling for age in the multivariate analysis, the trend did not reach a statistical significance.
Conclusion: The risk for capsular rupture is higher in patients with a history of intravitreal anti-VEGF injections.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2021 Raul Velez-Montoya et al.)
Databáze: MEDLINE
Externí odkaz: